Anixa Biosciences Inc ANIX

$2.77 -0.16 (-5.46%)

Valuation

Market cap
101,858,000
Revenue TTM
$0
Net income TTM
$-10,930,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
290,300
Avg volume
299,704
Day's range
$2.73 – $2.93
Shares out
34,764,000
Stochastic %K
46%
Beta
0.51
Analysts
Strong Sell
Price target
$9.67

Price

Company profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of...

Show more

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate. Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Industry
Biotechnology
Sector
Healthcare
Phone
408 708 9808
Website
https://www.anixa.com
Address
3150 Almaden Expressway, Suite 250, San Jose, United States

Latest news

Stocktwits

dipsandchipssss Oct 2, 10:48 AM
$ANIX Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial
0 replies
stockobserver51 Oct 1, 7:34 PM
$ANIX If you won't listen, you'll have to feel the pain of your money losing its value. People have been getting ripped off here for nearly a decade. 🙈
0 replies
Rideabull Sep 30, 2:44 PM
$ANIX So let me get this straight, the executive team gets salaries well beyond what they deserve and then they keep buying shares at the dip to prop it up. I can only hope they know something we don't.
2 replies
DD87 Sep 29, 2:35 PM
$ANIX never any volume. I do think it goes back to 3$ this week for a nice swing.
0 replies
dipsandchipssss Sep 29, 12:54 PM
$ANIX the amount of shares purchased from executives over last year is insane. This has to mean something
0 replies
CEOBuysDisclosures Sep 28, 2:50 PM
$ANIX CEO purchased 7,000 shares at $2.78 for a total of $19,460. KUMAR AMIT now owns 672,000 shares. https://ceo-buys.com
0 replies
dipsandchipssss Sep 28, 1:31 PM
$ANIX $ANIX insider buying continues 👀 CEO Amit Kumar just purchased 7,000 shares around $2.78 (~$19.5K). Director Arnold Baskies also purchased 5,000 shares around $2.76 (~$13.8K). Add that to recent director Lewis Titterton Jr.’s 49,036-share purchase (~$132K). Multiple insiders buying in the ~$2.70s. 🧬📈
0 replies
stockToph Sep 27, 2:27 PM
$ANIX share price is reflecting considerable skepticism, but the behavior of its insiders doesn’t look like the behavior of people who share that pessimism. They’re buying meaningful amounts of stock with their OWN money after the delays, after the latest financial results, and around the current depressed valuation. That suggests they believe the market is undervaluing what ANIX has; not that they know the outcome of the trials, BUT, that they’re willing to put substantial personal capital behind their assessment of the risk/reward.
2 replies